Mammary Cell News Volume 13.15 | Apr 22 2021

    By
    Justin.choi
    -
    0
    78







    2021-04-22 | MCN 13.15


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.15 – 22 April, 2021
    TOP STORY

    The Bone Microenvironment Invigorates Metastatic Seeds for Further Dissemination

    Researchers demonstrated that the bone microenvironment facilitated breast and prostate cancer cells to further metastasize and establish multi-organ secondary metastases.
    [Cell]

    AbstractPress ReleaseGraphical Abstract

    Virtual Conference Exhibition: Organoids
    PUBLICATIONSRanked by the impact factor of the journal

    The Bone Microenvironment Increases Phenotypic Plasticity of ER+ Breast Cancer Cells

    The authors discovered that the osteogenic niche transiently and reversibly reduced estrogen receptor (ER) expression and activities specifically in bone micrometastases, leading to endocrine resistance.
    [Developmental Cell]

    Full ArticleGraphical Abstract

    High Estrogen Receptor Alpha Activation Confers Resistance to Estrogen Deprivation and Is Required for Therapeutic Response to Estrogen in Breast Cancer

    Scientists demonstrated that estrogen receptor alpha (ER) overexpression conferred resistance to estrogen deprivation through ER activation in human ER+ breast cancer cells and xenografts grown in mice.
    [Oncogene]

    Abstract

    Up-Regulated circBACH2 Contributes to Cell Proliferation, Invasion, and Migration of Triple-Negative Breast Cancer

    Utilizing a circRNA microarray dataset, four circRNAs were identified to be abnormally expressed in TNBC. Among them, circBACH2 was most significantly elevated in TNBC cancerous tissues and its high expression was positively correlated to the malignant progression of TNBC patients.
    [Cell Death & Disease]

    Full Article

    Drug-Resistant Cancer Cell-Derived Exosomal EphA2 Promotes Breast Cancer Metastasis via the EphA2-Ephrin A1 Reverse Signaling

    Investigators demonstrated that drug-resistant cell-derived exosomes promoted the invasion of sensitive breast cancer cells.
    [Cell Death & Disease]

    Full Article

    JAC1 Suppresses Proliferation of Breast Cancer through the JWA/p38/SMURF1/HER2 Signaling

    Scientists developed a non-cytotoxic JWA gene activating compound 1 (JAC1) to inhibit the proliferation of HER2-positive breast cancer cells in vitro and in vivo experimental models.
    [Cell Death Discovery]

    Full Article

    Establishment and Characterization of a New Spontaneously Immortalized ER−/PR−/HER2+ Human Breast Cancer Cell Line, DHSF-BR16

    A new spontaneously immortalized breast cancer cell line, DHSF-BR16 cells, was isolated from the primary invasive ductal carcinoma of a 74-years old female patient, treated with neoadjuvant chemotherapy and disease-free five-years after adjuvant chemotherapy.
    [Scientific Reports]

    Full Article

    Selection of Aptamers against Triple Negative Breast Cancer Cells Using High Throughput Sequencing

    Researchers identified new aptamers that bound to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing.
    [Scientific Reports]

    Full Article

    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    REVIEWS

    Signaling Pathways Governing Breast Cancer Stem Cells Behavior

    Scientists discuss known signaling mechanisms involved in the stimulation or prevention of breast cancer stem cells’ self-renewal, metastasis, and tumorigenesis.
    [Stem Cell Research & Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Reify Health Powers Patient Recruitment and Enrollment Across AstraZeneca’s Extensive Breast Cancer Clinical Trial Pipeline

    Reify Health, Inc. announced that AstraZeneca has selected StudyTeam, a patient enrollment management platform, to accelerate clinical development across its breast cancer investigational therapy portfolio.
    [Reify Health, Inc.]

    Press Release

    Aion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells

    Aion Therapeutic, Inc. announced that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and TNBC cells by direct cytotoxicity.
    [Aion Therapeutic, Inc. (Cision US Inc.)]

    Press Release

    FEATURED EVENT

    Healthy Aging

    May 25 – 27, 2022
    Hinxton, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellowships – Clinical Cancer Prevention

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Senior Manager – Medical Affairs Oncology

    Gilead Sciences, Inc. – Austria, Vienna

    Director – Cancer Research

    Cyprus Cancer Research Institute – Republic of Cyprus

    Postdoctoral Position – Breast Cancer Therapy

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    Postdoctoral Fellow – Breast Cancer Research

    University of South Carolina – Columbia, South Carolina, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter